Abstract
Background Children with sickle cell anemia (SCA) in Sub-Saharan Africa are at high risk of sickle cerebrovascular injury (SCVI). Hydroxyurea, a commonly used disease-modifying therapy, may prevent or decrease SCVI for reduced incident stroke, stroke risk and potentially cognitive dysfunction. We aim to test the impact of daily hydroxyurea therapy on these outcomes in Ugandan children with SCA. We hypothesize that hydroxyurea therapy over 36 months will prevent, stabilize or improve these complications of SCA.
Methods The BRAIN SAFE II study is an open-label, single-arm trial of daily hydroxyurea for 270 children with SCA (HbSS) in Uganda, ages 3-9 years. Following baseline assessments, participants began hydroxyurea therapy and clinically followed per local guidelines. Standard hydroxyurea dose is escalated to maximum tolerated dose (MTD). SCVI is assessed by cerebral arterial velocity using Doppler ultrasound, with cognitive function determined by formal neurocognitive testing (primary outcomes). Structural SCVI is assessed by magnetic resonance imaging (MRI) and angiography (MRA) in a sub-sample of 90 participants ages ≥5 years, along with biomarkers of anemia, inflammation and malnutrition (secondary outcomes). At trial midpoint (18 months) and completion (36 months), primary outcomes will be compared to participants’ baseline to determine hydroxyurea impact and relationships to secondary outcomes.
Conclusion This open-label, single-arm trial will examine the impact of hydroxyurea on preventing or ameliorating SCA SCVI in children, assessed by reducing incident stroke, stroke risk and neurocognitive dysfunction. Trial results will provide important insight into the role of hydroxyurea therapy on critical manifestations of SCVI in children with SCA.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04750707
Funding Statement
Funding to conduct the trial is provided by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Fogarty International Centre at the National Institutes of Health (NIH) (1R01HD096559, Idro, Green).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Makerere University,School of medicine ethics and research committe(SOMREC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Trial registration: https://clinicaltrials.gov/ct2/show/NCT04750707 (registered 11 February, 2021)
Protocol version: BRAIN SAFE II Protocol Version 3.0, 02 Mar 2022.
Supported by award R01HD096559 (Idro, Green) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the Fogarty International Center, both at the National Institutes of Health (NIH). Study drug was donated by AddMedica/Theravia, France.
The authors declare that they have no competing interests.
Abbreviations
- AE
- Adverse event
- AIDS
- Acquired immunodeficiency syndrome
- BRAIN SAFE
- Hydroxyurea for the prevention of neurologic and cognitive impairment in children with sickle cell anaemia
- CRF
- Case Report form
- CRO
- Contract Research Organisation
- DSMC
- Data Safety and Monitoring Committee
- GCP
- Good Clinical Practice
- HIV
- Human Immuno-deficiency virus
- IEC/IRB/REC
- Independent Ethics Committee / Institutional Review Board
- ITT
- Intention to treat
- ICH
- The International Conference on Harmonisation
- SD
- standard deviation
- NfLC
- Neurofilament light chain
- SOP
- standard operating procedure
- SP
- Sulfadoxine-pyrimethamine
- SSA
- Sub-Saharan Africa
- URTI
- Upper respiratory tract infection
- RBC
- Red Blood Cells
- SAE
- Serious Adverse Event
- WHO
- World Health Organization
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos